Complete Hematologic Response in a Patient with Multiple Pretreated Angioimmunoblastic T-cell Lymphoma After Belinostat Therapy Followed by Allogeneic Stem Cell Transplantation: A Case Report

Overview

Journal Clin Case Rep

Date 2024 Jul 9

PMID 38979088

Authors

Sigrid De Wilde

Carlos Graux

Affiliations

Soon will be listed here.

Abstract

Key Clinical Message: Belinostat therapy followed by hematopoietic stem cell transplantation is a promising salvage strategy for heavily pretreated patients with peripheral T-cell lymphoma.

Abstract: Effective treatments for peripheral T-cell lymphoma in the relapsed and refractory (r/r) setting are limited. However, with the development and approval of innovative therapies, effective therapeutic options are becoming available for this patient population. This case report describes the treatment course of a patient with multiple r/r nodal follicular T-helper cell lymphoma of angioimmunoblastic type. Treatment with the histone deacetylase inhibitor belinostat as bridging, enabled allogeneic stem cell transplantation and resulted in a durable complete hematologic response for at least 21 months post-transplantation.

References

Foss F, Advani R, Duvic M, Hymes K, Intragumtornchai T, Lekhakula A . A Phase II trial of Belinostat (PXD101) in patients with relapsed or refractory peripheral or cutaneous T-cell lymphoma. Br J Haematol. 2014; 168(6):811-9. DOI: 10.1111/bjh.13222. View

Savage K, Horwitz S, Advani R, Haaber Christensen J, Domingo-Domenech E, Rossi G . Role of stem cell transplant in CD30+ PTCL following frontline brentuximab vedotin plus CHP or CHOP in ECHELON-2. Blood Adv. 2022; 6(19):5550-5555. PMC: 9647727. DOI: 10.1182/bloodadvances.2020003971. View

Reboursiere E, Le Bras F, Herbaux C, Gyan E, Clavert A, Morschhauser F . Bendamustine for the treatment of relapsed or refractory peripheral T cell lymphomas: A French retrospective multicenter study. Oncotarget. 2016; 7(51):85573-85583. PMC: 5356759. DOI: 10.18632/oncotarget.10764. View

Sabattini E, Pizzi M, Tabanelli V, Baldin P, Sacchetti C, Agostinelli C . CD30 expression in peripheral T-cell lymphomas. Haematologica. 2013; 98(8):e81-2. PMC: 3729886. DOI: 10.3324/haematol.2013.084913. View

Camus V, Etancelin P, Drieux F, Veresezan E, Picquenot J, Penther D . Complete hematologic response after belinostat treatment and allogeneic stem cell transplantation for multiple relapsed/refractory angioimmunoblastic T-cell lymphoma: A case report. Clin Case Rep. 2023; 11(6):e7623. PMC: 10290197. DOI: 10.1002/ccr3.7623. View

Aubrais R, Bouabdallah K, Chartier L, Herbaux C, Banos A, Brice P . Salvage therapy with brentuximab-vedotin and bendamustine for patients with R/R PTCL: a retrospective study from the LYSA group. Blood Adv. 2022; 7(19):5733-5742. PMC: 10539874. DOI: 10.1182/bloodadvances.2022008524. View

Ghione P, Faruque P, Mehta-Shah N, Seshan V, Ozkaya N, Bhaskar S . T follicular helper phenotype predicts response to histone deacetylase inhibitors in relapsed/refractory peripheral T-cell lymphoma. Blood Adv. 2020; 4(19):4640-4647. PMC: 7556143. DOI: 10.1182/bloodadvances.2020002396. View

Lee H, Kwitkowski V, Del Valle P, Ricci M, Saber H, Habtemariam B . FDA Approval: Belinostat for the Treatment of Patients with Relapsed or Refractory Peripheral T-cell Lymphoma. Clin Cancer Res. 2015; 21(12):2666-70. DOI: 10.1158/1078-0432.CCR-14-3119. View

Swerdlow S, Campo E, Pileri S, Lee Harris N, Stein H, Siebert R . The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood. 2016; 127(20):2375-90. PMC: 4874220. DOI: 10.1182/blood-2016-01-643569. View

10.

Horwitz S, OConnor O, Pro B, Illidge T, Fanale M, Advani R . Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial. Lancet. 2018; 393(10168):229-240. PMC: 6436818. DOI: 10.1016/S0140-6736(18)32984-2. View

11.

Sibon D . Peripheral T-Cell Lymphomas: Therapeutic Approaches. Cancers (Basel). 2022; 14(9). PMC: 9104854. DOI: 10.3390/cancers14092332. View

12.

Wagner S, Melchardt T, Egle A, Magnes T, Skrabs C, Staber P . Treatment with brentuximab vedotin plus bendamustine in unselected patients with CD30-positive aggressive lymphomas. Eur J Haematol. 2019; 104(3):251-258. PMC: 7065019. DOI: 10.1111/ejh.13368. View

13.

OConnor O, Horwitz S, Masszi T, Van Hoof A, Brown P, Doorduijn J . Belinostat in Patients With Relapsed or Refractory Peripheral T-Cell Lymphoma: Results of the Pivotal Phase II BELIEF (CLN-19) Study. J Clin Oncol. 2015; 33(23):2492-9. PMC: 5087312. DOI: 10.1200/JCO.2014.59.2782. View

14.

Lage L, Culler H, Reichert C, da Siqueira S, Pereira J . Angioimmunoblastic T-cell lymphoma and correlated neoplasms with T-cell follicular helper phenotype: from molecular mechanisms to therapeutic advances. Front Oncol. 2023; 13:1177590. PMC: 10169672. DOI: 10.3389/fonc.2023.1177590. View

15.

Mak V, Hamm J, Chhanabhai M, Shenkier T, Klasa R, Sehn L . Survival of patients with peripheral T-cell lymphoma after first relapse or progression: spectrum of disease and rare long-term survivors. J Clin Oncol. 2013; 31(16):1970-6. DOI: 10.1200/JCO.2012.44.7524. View

16.

Alaggio R, Amador C, Anagnostopoulos I, Attygalle A, de Oliveira Araujo I, Berti E . The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms. Leukemia. 2022; 36(7):1720-1748. PMC: 9214472. DOI: 10.1038/s41375-022-01620-2. View

17.

Richardson N, Kasamon Y, Chen H, De Claro R, Ye J, Blumenthal G . FDA Approval Summary: Brentuximab Vedotin in First-Line Treatment of Peripheral T-Cell Lymphoma. Oncologist. 2019; 24(5):e180-e187. PMC: 6516120. DOI: 10.1634/theoncologist.2019-0098. View

18.

Sorigue M, Kuittinen O . Controversies in the Front-Line Treatment of Systemic Peripheral T Cell Lymphomas. Cancers (Basel). 2023; 15(1). PMC: 9818471. DOI: 10.3390/cancers15010220. View

19.

Bolden J, Peart M, Johnstone R . Anticancer activities of histone deacetylase inhibitors. Nat Rev Drug Discov. 2006; 5(9):769-84. DOI: 10.1038/nrd2133. View

20.

Advani R, Skrypets T, Civallero M, Spinner M, Manni M, Kim W . Outcomes and prognostic factors in angioimmunoblastic T-cell lymphoma: final report from the international T-cell Project. Blood. 2021; 138(3):213-220. PMC: 8493974. DOI: 10.1182/blood.2020010387. View